Monocytes may be therapeutic target for a COVID-19 treatment

White blood cells called monocytes released into the blood from bone marrow have abnormal features in people who have COVID-19. This is according to a new study by University of Manchester immunologists at the Lydia Becker Institute.

The team from the Coronavirus Immune Response and Clinical Outcome (CIRCO) consortium says the abnormalities are greater in patients with severe infection.

By spotting the abnormal monocytes early, doctors may be able to predict which patients are more likely to develop severe disease.

The study

The study provides the strongest evidence yet that monocytes may be an important therapeutic target for a COVID-19 treatment.

It is not yet clear, says the team, if abnormal monocytes are released from the bone marrow or if the changes happen after they enter the blood.

However, treatments preventing their release from bone marrow may help reduce the exaggerated immune response that contributes to poor outcomes in patients with severe COVID-19.

The paper in Science Immunology is the first to be published by the consortium, based at The University of Manchester.

Importance of monocytes

Scientists already know that monocytes – the largest type of white blood cell  –  are an important component in the lung during infection and play roles in protection and repair.

The team analysed over a hundred blood samples from COVID-19 patients admitted to four hospitals across Greater Manchester to search for biomarkers that signal progression to severe disease at various points in their hospital stay.

Dr John Grainger, Deputy Director of the Lydia Becker and a senior author on the study said: “Our work once again highlights the importance of the innate immune system in COVID-19, we’re excited to be able to finally share the results of our study and hope that it can better inform treatments for this devastating disease”.

Immunological expertise

The CIRCO consortium draws together immunological expertise from the Lydia Becker Institute with clinicians and research nurses at Salford Royal, Wythenshawe, North Manchester and Manchester Royal NHS Trusts.

It was set-up during the first wave of the pandemic to collect longitudinal samples from patients with diagnosed COVID-19; studying their immune response from hospital admission through to outcome.

The study was in part supported by a rapid response COVID-19 award from The Kennedy Trust for Rheumatology Research.

Prof. Tracy Hussell, Director of the Lydia Becker Institute, added: “Thanks to all members of the CIRCO team for their hard work on this study it has been a great example of scientists and clinicians working together to give new insight into this infection”.

Image credit: CDC


Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free